AN EVALUATION OF THE BUDGET IMPACT OF THE NEW 20% SUBCUTANEOUS IMMUNOGLOBULIN (IG20GLY) FOR THE MANAGEMENT OF PRIMARY IMMUNODEFICIENCY DISEASES IN SWITZERLAND

被引：0
|
作者：
Pollock, R. F. [1 ]
Meckley, L. M. [2 ]
机构：
[1] Ossian Hlth Econ & Commun GmbH, Basel, Switzerland
[2] Shire Plc, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY27
引用
收藏
页码：A549 / A549
页数：1
相关论文
共 50 条
  • [1] An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland
    Pollock, Richard F.
    Meckley, Lisa M.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 223 - 229
  • [2] Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies
    Paris, Kenneth
    Haddad, Elie
    Borte, Michael
    Brodszki, Nicholas
    Derfalvi, Beata
    Marodi, Laszlo
    Hussain, Iftikhar
    Darter, Amy
    Engl, Werner
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    IMMUNOTHERAPY, 2019, 11 (05) : 397 - 406
  • [3] Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases
    Dumas, Todd
    Berry, N. Seth
    Wolfsegger, Martin
    Jolles, Stephen
    McCoy, Barbara
    Yel, Leman
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 71 : 404 - 410
  • [4] Onboarding Experience of Pediatric Patients With Primary Immunodeficiency Diseases With Subcutaneous Human Immune Globulin 20% (Ig20Gly)
    Paris, Kenneth
    Hussain, Iftikhar
    Gupta, Sudhir
    Wang, Ping
    Mccoy, Barbara
    Rabbat, Christopher J.
    Yel, Leman
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB268 - AB268
  • [5] Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases
    Gupta, Sudhir
    Stein, Mark
    Hussain, Iftikhar
    Paris, Kenneth
    Engl, Werner
    McCoy, Barbara
    Rabbat, Christopher J.
    Yel, Leman
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (03) : 271 - +
  • [6] Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials
    Lisa M. Meckley
    Yanyu Wu
    Diane Ito
    Todd Berner
    Barbara McCoy
    Leman Yel
    BMC Immunology, 21
  • [7] Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials
    Meckley, Lisa M.
    Wu, Yanyu
    Ito, Diane
    Berner, Todd
    McCoy, Barbara
    Yel, Leman
    BMC IMMUNOLOGY, 2020, 21 (01)
  • [8] Infusion parameters, safety, and practical guidance for the manual administration of subcutaneous immunoglobulin 20% (Ig20Gly)
    Grosse-Kreul, Dorothea
    Allen, Crystal
    Kalicinsky, Chrystyna
    Keith, Paul K.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2024, 20 (01):
  • [9] IG20GLY TOLERABILITY AND INFUSION CHARACTERISTICS ACROSS AGE GROUPS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
    Paris, K.
    Suez, D.
    Gupta, S.
    Hussain, I.
    Stein, M.
    Wang, P.
    McCoy, B.
    Yel, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S48 - S49
  • [10] Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases
    Paris, Kenneth
    Suez, Daniel
    Gupta, Sudhir
    Hussain, Iftikhar
    Stein, Mark
    Wang, Ping
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB116 - AB116
12345